Cargando…
NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
Idiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 pa...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598748/ https://www.ncbi.nlm.nih.gov/pubmed/36289624 http://dx.doi.org/10.3390/biomedicines10102362 |
_version_ | 1784816427987894272 |
---|---|
author | Cheng, Shih-Lung Sheu, Chau-Chyun Chian, Chih-Feng Hsu, Jeng-Yuan Kao, Kuo-Chin Hang, Liang-Wen Lin, Ching-Hsiung Fang, Wen-Feng Wang, Hao-Chien Perng, Diahn-Warng |
author_facet | Cheng, Shih-Lung Sheu, Chau-Chyun Chian, Chih-Feng Hsu, Jeng-Yuan Kao, Kuo-Chin Hang, Liang-Wen Lin, Ching-Hsiung Fang, Wen-Feng Wang, Hao-Chien Perng, Diahn-Warng |
author_sort | Cheng, Shih-Lung |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 patients (aged 74.6 ± 9.1 years and 83.2% men) with IPF were collected over 2 years (2018−2020) from medical centers in Taiwan at baseline, 1 month, and subsequent 3-month intervals. Treated patients (n = 88) received the antifibrotics nintedanib or pirfenidone, compared with the untreated group (n = 13). The 2-year assessment revealed overall preserved lung functionality in the treated patients, with insignificant changes from baseline for percent predicted forced vital capacity or FVC (±1.7%). The presence of respiratory comorbidities significantly increased the risk of both AE and death (with or without AE) over the full study duration. Furthermore, the decline of predicted FVC significantly increased with the risk of acute exacerbations (AE) in the second year. Overall, antifibrotic medication was beneficial in stalling IPF progression, reducing AEs, and delaying mortality in the treated cohort, despite their lower baseline lung functions. Further, no new safety concerns over antifibrotic treatments were observed for the Taiwanese population. |
format | Online Article Text |
id | pubmed-9598748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95987482022-10-27 NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan Cheng, Shih-Lung Sheu, Chau-Chyun Chian, Chih-Feng Hsu, Jeng-Yuan Kao, Kuo-Chin Hang, Liang-Wen Lin, Ching-Hsiung Fang, Wen-Feng Wang, Hao-Chien Perng, Diahn-Warng Biomedicines Article Idiopathic pulmonary fibrosis (IPF) causes progressive lung fibrosis with subsequent fatality and has limited treatment options. NICEFIT is the first Taiwan-based prospective, observational, and non-interventional registry for IPF progression under routine clinical practice in Taiwan. Data on 101 patients (aged 74.6 ± 9.1 years and 83.2% men) with IPF were collected over 2 years (2018−2020) from medical centers in Taiwan at baseline, 1 month, and subsequent 3-month intervals. Treated patients (n = 88) received the antifibrotics nintedanib or pirfenidone, compared with the untreated group (n = 13). The 2-year assessment revealed overall preserved lung functionality in the treated patients, with insignificant changes from baseline for percent predicted forced vital capacity or FVC (±1.7%). The presence of respiratory comorbidities significantly increased the risk of both AE and death (with or without AE) over the full study duration. Furthermore, the decline of predicted FVC significantly increased with the risk of acute exacerbations (AE) in the second year. Overall, antifibrotic medication was beneficial in stalling IPF progression, reducing AEs, and delaying mortality in the treated cohort, despite their lower baseline lung functions. Further, no new safety concerns over antifibrotic treatments were observed for the Taiwanese population. MDPI 2022-09-22 /pmc/articles/PMC9598748/ /pubmed/36289624 http://dx.doi.org/10.3390/biomedicines10102362 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cheng, Shih-Lung Sheu, Chau-Chyun Chian, Chih-Feng Hsu, Jeng-Yuan Kao, Kuo-Chin Hang, Liang-Wen Lin, Ching-Hsiung Fang, Wen-Feng Wang, Hao-Chien Perng, Diahn-Warng NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
title | NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
title_full | NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
title_fullStr | NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
title_full_unstemmed | NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
title_short | NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan |
title_sort | nicefit—a prospective, non-interventional, and multicentric study for the management of idiopathic pulmonary fibrosis with antifibrotic therapy in taiwan |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9598748/ https://www.ncbi.nlm.nih.gov/pubmed/36289624 http://dx.doi.org/10.3390/biomedicines10102362 |
work_keys_str_mv | AT chengshihlung nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT sheuchauchyun nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT chianchihfeng nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT hsujengyuan nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT kaokuochin nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT hangliangwen nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT linchinghsiung nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT fangwenfeng nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT wanghaochien nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan AT perngdiahnwarng nicefitaprospectivenoninterventionalandmulticentricstudyforthemanagementofidiopathicpulmonaryfibrosiswithantifibrotictherapyintaiwan |